An investigation for investors in Geron Corporation (NASDAQ: GERN) shares over potential securities laws violations by Geron Corporation was announced and NASDAQ: GERN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/11/2018 -- An investigation was announced for investors in NASDAQ: GERN shares over potential securities laws violations by Geron in connection with certain financial statements.
Investors who purchased shares of Geron Corporation (NASDAQ: GERN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Geron Corporation (NASDAQ: GERN) concerning whether a series of statements by Geron Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of Geron Corporation (NASDAQ: GERN) rose to as high as $6.68 per share on March 19, 2018
On March 27, 2017, STAT published a report by Adam Feuerstein stating that Geron's recent stock gains were due to "flimsy" claims regarding the efficacy of imetelstat, Geron's experimental treatment for myelofibrosis. The report states that available data for imetelstat undercuts Geron's representations as to the drug's efficacy.
Shares of Geron Corporation (NASDAQ: GERN) declined on April 2, 2018 t as low as $3.77 per share.
Those who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com